Raised to Date: Raised: $95,809
Aggregate Commitments $
Equity - Common
Rolling Commitments $
Are you, or is someone in your life, impacted by Alzheimer’s? Is so, Neurotez Inc. could be the investment you’ve been looking for. Their highly experienced team is developing a drug to treat Leptin deficiency in Alzheimer’s patients and/or act as a preventative for those who are at risk, and their drug might just be the missing piece needed to help fight this terrible disease.
Neurotez Inc. is on a mission to become the world leaders in biotechnology and to help Alzheimer’s patients with drugs that are both safe and efficacious. Their primary goal is to develop a Leptin product as an innovative hormone replacement therapy for Alzheimer’s disease and/or as a preventative for those who are at risk. Today’s medications provide limited relief, and current efforts, which focus on removing either Abeta or tau deposits from the brain, have not generated any effective drugs for the last 18 years. Neurotez is here to change that -- by focusing on Leptin instead and attacking the disease in a new way. So far, Neurotez has been nominated as the Most Promising Private Company in 2015 by the Biotechnology Industry Organization, as well as a 2010 Incubator Company to Watch at the NJTC Gala Awards. Add in that their team has deep experience and success with thousands of publications in Alzheimer’s, and you can see why Neurotez might just be the Alzheimer's weapon we’ve been waiting for.
The Bottom Line:
Neurotez Inc. is changing the game when it comes to treating and fighting Alzheimer’s. Their Leptin product attacks the disease in a new way, and with Alzheimer’s affecting more than five million Americans and 18 million patients worldwide, we need all the help we can get. This innovative treatment might be just what patients need to help with -- or prevent -- the devastating effects of Alzheimer’s.
|Offering Name||Close Date||Platform||Valuation/Cap||Total Raised||Security Type||Status||Reg Type|
|Neurotez||01/27/2023||Netcapital||$45,272,228||$10,648||Equity - Common||Active||RegCF|
|Neurotez||03/10/2022||StartEngine||$44,870,036||$33,845||Equity - Common||Funded||RegCF|
|Neurotez||06/24/2021||Netcapital||$21,959,058||$255,718||Equity - Common||Funded||RegCF|
|Neurotez||02/26/2018||Netcapital||$24,544,690||$95,809||Equity - Common||Funded||RegCF|
Upgrade to gain access
- Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- , plus
- Company specific
- Advanced company search ( )
- Get Edge Annual
- Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- In-depth risk ratings for every raise
- Get Edge Pro Annual